Genmab A GMAB
NASDAQ GMAB
$34.74 +0.21 (+0.61%)
At close: Sep 18, 2026 · 4:00 PM EDT

Genmab A (GMAB) Net Margin Growth (3y) (2021 - 2025)

Analysis

Genmab A (GMAB) Net Margin Growth (3y) (2021 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn 388.00
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn -15,026.00
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn -374.00
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn -44.00
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn -13,815.00
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn 6,620.00
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn 9,934.00
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn -2,059.00
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn -1.86 Mn
10 Genmab A 2.23 Bn 728.64 Mn 1.07 Bn -1,578.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -2,975.00
Sep 30, 2024 3,280.00
Jun 30, 2024 -5,780.00
Dec 31, 2023 -23,715.00
Sep 30, 2023 -107.18 Bn
Jun 30, 2022 6,437.00
Dec 31, 2021 -220,164.00